Schizophrenia has a lifetime prevalence of about 1% worldwide with annual associated costs estimated to be more than $150 billion in the United States. Further, individuals with schizophrenia have a mean life expectancy about 15 years shorter than the general population. Despite continuous improvements in medications and traditional “talk” therapy used to treat this condition, many individuals who suffer from schizophrenia are unable to return to their full potential. An estimated 33% with schizophrenia do not receive clinically significant benefit in symptom reduction with currently available treatments, highlighting an unmet need for novel approaches to treat this serious mental illness (SMI).
For more information about any of our current studies, please contact us:
Phone: 508-856-Mind(6463)
Email: Mind@umassmed.edu
